Key result
Olmesartan reversed daunorubicin-induced cardiac toxicity in rats, improving cardiac function and reducing oxidative stress markers.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for olmesartan in anthracycline cardiotoxicity; should not change practice pending human trials.
The aim was to evaluate the role of the combination of olmesartan, an angiotensin II (Ang II) receptor blocker (ARB), with daunorubicin (DNR) in reducing cardiac toxicity in rats. DNR was administered at a dose of 3 mg/kg/day every other day for 12 days. Olmesartan was administered orally every day for 12 days. Rats treated with DNR alone showed cardiac toxicity as evidenced by worsening cardiac function, elevation of malondialdehyde level in heart tissue and decreased in the level of total glutathione peroxidase activity; treatment with ARB reversed these changes. Furthermore, ARB treatment down-regulated matrix metalloproteinase-2 expression, myocardial expression of Ang II, attenuated the increased protein expressions of p67phox and Nox4 and reduced oxidative stress-induced DNA damage evaluated by expression of 8-hydroxydeoxyguanosine. In conclusion, the result demonstrated that Ang II and oxidative stress play a key role in anthracycline-induced cardiotoxicity and that treatment with ARB will be beneficial against DNR-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Arozal et al. (2010) studied Daunorubicin-induced cardiotoxicity. Olmesartan vs. Daunorubicin alone was evaluated on Cardiac toxicity (cardiac function, malondialdehyde level, glutathione peroxidase activity). Olmesartan reversed daunorubicin-induced cardiac toxicity in rats, improving cardiac function and reducing oxidative stress markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: